← Return to all swing-trade opportunities
EW — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 35.0/100
Why this was flagged
EW was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 35.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner found Edwards Lifesciences Corp (EW) using a pattern called an Oversold Bullish Reversal. This means the stock price has dropped quite a bit, and there are signs it might start moving up again. The Relative Strength Index (RSI), which is a tool used to see if a stock is "oversold," is at 15. Being near 15 suggests the selling may have been heavy. Also, more people are trading this stock than usual, as the volume is 1.37 times higher than its recent average.
What the price plan means
The entry zone is between $83.82 and $84.38. If the price moves up, the first goal is $86.25, and the second goal is $87.46. To manage risk, a stop-loss is set at $82.61. This is an automatic exit point if the price drops too low. The reward-to-risk ratio is 2, which means the planned profit is twice as large as the potential loss.
What could make the idea fail
The scanner gave this setup a score of 35 out of 100. A lower score means the pattern is not very strong. If the price falls below $82.61, the bullish idea fails.
Important reminder
This information is for educational purposes only and does not represent a recommendation to trade.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (High confidence)
Edwards Lifesciences reported strong Q2 2026 results, characterized by a 13.6% year-over-year sales increase to $1.74 billion and earnings per share that beat analyst estimates. The company raised its full-year 2026 sales guidance, driven by double-digit growth in its TAVR franchise and improved expectations for transcatheter mitral and tricuspid therapies (TMTT). While one report noted revenue fell short of certain estimates, the stock responded positively to the overall growth and increased outlook. Analysts maintain a positive outlook with a median price target of $100.0.
Potentially supportive context
- Reported 13.6% year-over-year sales increase to $1.74 billion in Q2.
- Raised full-year 2026 sales guidance for constant currency growth and specific product categories.
- Achieved earnings per share that surpassed analyst expectations.
Risks and caution items
- Insider trading activity showed 24 sales with no purchases in the last six months.
- One report indicated revenue fell short of certain estimates despite the overall beat on EPS.
- Stock performance remains sensitive to shifts in growth expectations and competitive dynamics.
Latest reviewed article: Jul 23, 2026 9:22 pm
Recent related articles
Edwards Lifesciences (EW) saw its stock jump by 6.1% following a strong second-quarter report that highlighted double-digit revenue growth and an increased full-year sales outlook for 2026. The company reported a 13.6% year-over-year sales increase to $1.74 billion, with significant contributions from…
Edwards Lifesciences (NYSE:EW) reported strong second-quarter results, surpassing analyst expectations for both earnings and revenue, and subsequently saw its shares jump over 6% after hours. The company also raised its full-year sales guidance for constant currency growth and specific product categories like…
EDWARDS LIFESCIENCES ($EW) reported its Q2 2026 earnings, with earnings per share beating estimates but revenue falling short. The stock rose 1.31% following the announcement. The article also details recent insider trading, hedge fund activity, government contracts, congressional stock trading, and analyst…
Edwards Lifesciences (NYSE: EW) is preparing to release its second-quarter earnings, with analysts anticipating EPS of 74 cents on revenue of $1.7 billion. Investors are keenly watching for continued momentum in the company's TAVR business and transcatheter mitral and tricuspid therapies (TMTT)…
AtriCure Inc. is preparing to report its second-quarter earnings, with analysts expecting an adjusted loss on strong revenue growth. The company faces new competition in the surgical left atrial appendage closure market from Edwards Lifesciences, but analysts believe AtriCure's established position and…
This article provides key metrics for the US28176EAD0 bond issued by Edwards Lifesciences Corporation. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief overview of Edwards Lifesciences Corp.'s business operations…
Edwards Lifesciences stock is maintaining a steady valuation driven by strong growth in its transcatheter heart valve (THV) revenue, with recent annual figures showing double-digit expansion and high profitability. The company reported approximately $6.0 billion in total revenue, with THV therapies contributing…
EDWARDS LIFESCIENCES LLC disclosed $280,000 in lobbying expenses for Q2 2026, covering issues such as patient access to breakthrough products, medical innovation policies, and FDA reauthorization. Insiders at EW have primarily sold shares in the last six months, totaling 24 sales with…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Current volume is at least 1.25x the 20-day average volume.
- RSI is near oversold territory with bullish candle confirmation.